#1 Clinical Trials Search in Europe

Gskvx000000017033

This article discusses clinical trials investigating the use of GSKVx000000017033, a novel drug candidate, for the treatment of chronic hepatitis B. The trials aim to assess the safety, efficacy, and immune response of this drug when used alone or in combination with other therapies in patients with chronic hepatitis B who are already on nucleos(t)ide analogue therapy.

Table of Contents

What is GSKVX000000017033?

GSKVX000000017033 is an experimental drug being developed to treat chronic hepatitis B (CHB), a long-lasting liver infection caused by the hepatitis B virus[1]. This drug is part of a new approach to treating CHB, which combines different types of medications to potentially improve outcomes for patients.

How Does It Work?

GSKVX000000017033 is a component of a therapeutic vaccine called GSK3528869A. This vaccine is designed to stimulate the immune system to fight against the hepatitis B virus. It works differently from traditional medications and is used in combination with other treatments to potentially enhance the body’s ability to control or eliminate the virus[1][2].

Clinical Trials

The drug is currently being studied in clinical trials to evaluate its safety and effectiveness. Two main studies are underway:

  1. A Phase I/II trial combining GSKVX000000017033 with other components (GSK3528869A) and viral vector vaccines[1].
  2. A Phase II trial testing GSKVX000000017033 as part of GSK3528869A in combination with an anti-sense oligonucleotide (ASO) treatment[2].

These trials aim to determine how well the treatment works and if it’s safe for patients with chronic hepatitis B who are already taking standard antiviral medications.

Potential Benefits

The potential benefits of GSKVX000000017033 as part of the GSK3528869A treatment include:

  • Reduction in hepatitis B surface antigen (HBsAg) levels[1][2]
  • Possible HBsAg loss, which is a sign of better control over the virus[1][2]
  • Stimulation of the immune system to fight against the hepatitis B virus[1][2]
  • Potential for achieving a sustained virologic response (SVR), which means the virus is undetectable in the blood for a prolonged period[2]

Safety and Side Effects

As with any new treatment, safety is a primary concern. The clinical trials are closely monitoring for any side effects or adverse events. Some potential side effects being watched for include:

  • Injection site reactions (redness, pain, swelling)[2]
  • Systemic reactions (such as fever or fatigue)[2]
  • Changes in blood tests, including liver function tests[2]

It’s important to note that the full safety profile of GSKVX000000017033 is still being determined through these clinical trials.

Who Can Receive This Treatment?

Currently, GSKVX000000017033 is only available through clinical trials. Participants in these trials typically need to meet specific criteria, including:

  • Adults aged 18-65 years with chronic hepatitis B[1][2]
  • Patients who have been on stable antiviral therapy (nucleos(t)ide analogues) for at least 6-24 months[1][2]
  • No evidence of liver cirrhosis or hepatocellular carcinoma (liver cancer)[1][2]
  • Specific levels of hepatitis B virus in the blood and liver function tests within certain ranges[1][2]

Conclusion

GSKVX000000017033, as part of the GSK3528869A therapeutic vaccine, represents a promising new approach to treating chronic hepatitis B. By combining different treatment strategies, researchers hope to improve outcomes for patients living with this persistent viral infection. While the results are encouraging, it’s important to remember that this treatment is still in the experimental stage. Patients interested in this treatment should discuss current options and potential clinical trial participation with their healthcare providers.

Aspect Details
Drug Name GSKVx000000017033
Trial Phase Phase I/II and Phase II
Target Condition Chronic Hepatitis B
Patient Population Adults (18-65 years) with chronic HBV on stable NA therapy
Administration Route Intramuscular injection
Primary Objectives Safety, efficacy, and immunogenicity assessment
Key Efficacy Measures HBsAg reduction, HBV DNA suppression, sustained virologic response
Safety Monitoring Adverse events, laboratory abnormalities, serious adverse events
Immunogenicity Assessments Anti-HBc and anti-HBs antibodies, T-cell responses

FAQ

  • What is GSKVx000000017033? GSKVx000000017033 is an experimental drug being studied for the treatment of chronic hepatitis B. It is part of a therapeutic vaccine approach that aims to boost the immune system's response against the hepatitis B virus.
  • Who is eligible to participate in these clinical trials? Generally, adults aged 18-65 with chronic hepatitis B who are stable on nucleos(t)ide analogue therapy are eligible. Specific criteria include having HBV DNA levels below 90 IU/mL and HBsAg levels above 100 IU/mL.
  • What are the main goals of these clinical trials? The main goals are to evaluate the safety, efficacy, and immune response of GSKVx000000017033 when used alone or in combination with other therapies. The trials also aim to assess if the treatment can lead to a sustained virologic response in patients.
  • How is the drug administered? GSKVx000000017033 is administered as an intramuscular injection. The dosing schedule and frequency vary depending on the specific trial protocol.
  • What are the potential benefits of this new treatment approach? The potential benefits include improved control of the hepatitis B virus, possible reduction in HBsAg levels, and potentially achieving a functional cure for some patients. However, it's important to note that these benefits are still being investigated in the clinical trials.

Ongoing Clinical Trials on Gskvx000000017033

  • Study on the Safety and Effectiveness of GSKVX000000008866 and GSKVX000000009151 in Adults with Chronic Hepatitis B on Nucleotide Analogue Therapy

    Not recruiting

    1
    Investigated drugs:
    Belgium Germany Spain

  • Study on Safety and Efficacy of Bepirovirsen and Drug Combination for Chronic Hepatitis B in Patients on Nucleos(t)ide Analogue Therapy

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria France Germany Italy Poland +2

Glossary

  • Chronic Hepatitis B (CHB): A long-lasting liver infection caused by the hepatitis B virus that can lead to serious liver damage if left untreated.
  • HBsAg: Hepatitis B surface antigen, a protein on the surface of the hepatitis B virus. Its presence in the blood indicates an active hepatitis B infection.
  • Nucleos(t)ide analogue (NA) therapy: A type of antiviral medication used to treat chronic hepatitis B by suppressing the replication of the virus.
  • Sustained Virologic Response (SVR): A measure of treatment success, typically defined as undetectable levels of hepatitis B virus in the blood for a specified period after completing treatment.
  • HBeAg: Hepatitis B e-antigen, a protein produced by the hepatitis B virus. Its presence usually indicates that the virus is actively replicating.
  • Immunogenicity: The ability of a substance, such as a vaccine, to provoke an immune response in the body.
  • Therapeutic vaccine: A type of vaccine designed to treat an existing disease by boosting the body's natural immune response against it.
  • Anti-HBs antibodies: Antibodies produced by the immune system in response to the hepatitis B surface antigen. Their presence can indicate immunity to hepatitis B.
  • T-cells: A type of white blood cell that plays a central role in the immune response, helping to identify and destroy infected cells.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-gskvx000000008866-and-gskvx000000009151-in-adults-with-chronic-hepatitis-b-on-nucleotide-analogue-therapy/
  2. http://clinicaltrials.eu/trial/study-on-safety-and-efficacy-of-bepirovirsen-and-drug-combination-for-chronic-hepatitis-b-in-patients-on-nucleostide-analogue-therapy/